Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.56
+8.0%
$2.03
$0.95
$2.87
$21.27M0.13185,119 shs412,533 shs
Equillium, Inc. stock logo
EQ
Equillium
$0.39
-5.6%
$0.36
$0.27
$1.50
$13.97M1.86470,371 shs294,220 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.21
-12.5%
$0.29
$0.10
$1.36
$9.44M1.261.41 million shs558 shs
Oragenics, Inc. stock logo
OGEN
Oragenics
$1.38
+4.5%
$3.75
$1.30
$75.60
$1.14M0.95207,654 shs166,565 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.00%+10.23%+18.50%+125.71%-15.05%
Equillium, Inc. stock logo
EQ
Equillium
-0.24%+12.96%+26.67%-10.95%-52.40%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-20.29%-4.00%+51.32%-79.83%
Oragenics, Inc. stock logo
OGEN
Oragenics
-2.22%-6.38%-63.84%-76.47%-95.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.7726 of 5 stars
3.54.00.03.41.10.00.6
Equillium, Inc. stock logo
EQ
Equillium
2.2163 of 5 stars
3.24.00.00.00.61.70.6
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.7006 of 5 stars
0.03.00.00.01.72.50.0
Oragenics, Inc. stock logo
OGEN
Oragenics
0.0697 of 5 stars
0.02.00.00.01.10.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.00
Buy$10.00290.63% Upside
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00667.26% Upside
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OGEN, AYTU, NKGN, and EQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
6/30/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$81M0.28N/AN/A$4.64 per share0.55
Equillium, Inc. stock logo
EQ
Equillium
$41.10M0.34N/AN/A$0.54 per share0.72
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/A$0.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$15.84M-$0.720.00N/A2.37%3.51%0.91%9/24/2025 (Estimated)
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
-$20.66M-$33.63N/AN/AN/A-2,087.95%-486.56%N/A

Latest OGEN, AYTU, NKGN, and EQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q1 2025
Equillium, Inc. stock logo
EQ
Equillium
-$0.1850N/AN/AN/AN/AN/A
5/14/2025Q3 2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.27
1.03
0.87
Equillium, Inc. stock logo
EQ
Equillium
N/A
2.70
2.70
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
Oragenics, Inc. stock logo
OGEN
Oragenics
N/A
1.93
1.93

Institutional Ownership

CompanyInstitutional Ownership
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
Oragenics, Inc. stock logo
OGEN
Oragenics
18.71%

Insider Ownership

CompanyInsider Ownership
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.60%
Equillium, Inc. stock logo
EQ
Equillium
30.30%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
Oragenics, Inc. stock logo
OGEN
Oragenics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
1608.98 million8.65 millionNot Optionable
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.90 millionNot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable
Oragenics, Inc. stock logo
OGEN
Oragenics
5823,00010.98 millionN/A

Recent News About These Companies

Sarasota biotech company announces $20M public offering
Oragenics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.56 +0.19 (+8.02%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 0.00 (-0.20%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Equillium stock logo

Equillium NASDAQ:EQ

$0.39 -0.02 (-5.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 +0.02 (+4.09%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.21 -0.03 (-12.50%)
As of 02:58 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Oragenics stock logo

Oragenics NYSE:OGEN

$1.38 +0.06 (+4.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.41 +0.03 (+2.17%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.